Bioxodes is a clinical-stage biopharmaceutical company focused on novel therapies that address both thrombotic and inflammatory diseases. Its lead candidate, BIOX-101, delivers anticoagulant effects without increasing bleeding risk while simultaneously exerting anti-inflammatory action through modulation of neutrophils. This dual mechanism is expected to improve survival rates and recovery outcomes for patients suffering intracerebral hemorrhage (ICH) and related indications. The company holds a portfolio of granted and pending patents protecting BIOX-101 worldwide. Proceeds from recent financings are earmarked for expanding operations and advancing clinical development of the asset. To date, Bioxodes has secured €17.5 million in Series A funding, underscoring investor confidence in its therapeutic approach. No commercial revenue or user metrics have been disclosed at this stage of development.

Total raised

$26M

Funding rounds

5

Latest round

Series A

Latest activity

Dec 2025